NuGEN Genomics Grant Challenge Awarded to Support Characterization of Sarcoma Biogenesis and Identification of Novel Prognostic Markers to Guide Targeted Therapy.
NuGEN Technologies, Inc., a market leader in the development of solutions which make biological samples accessible for genomic analysis, has announced the winner of the NuGEN 2014 Genomics Grant Challenge. The winning study proposal, entitled "Identifying novel gene rearrangements in sarcoma biogenesis", was submitted by Dr. Bastiaan Tops, Dept. of Pathology.
The role of cancer mutations as predictors of sensitivity and resistance to targeted therapies is well-known and an important tool in personalized cancer medicine. Identification of gene rearrangements is equally important in understanding the molecular basis of certain tumor types, such as sarcoma, but detection and identification of clinically relevant gene rearrangements has been limited by available technologies. "Screening for gene rearrangements using PCR and FISH methods is costly and time-consuming. This project has been designed to use a much broader and more cost effective NGS based approach to detect both known and novel gene fusions that may be implicated in the disease mechanism", commented Dr. Tops. "We are very pleased to be the recipient of the Genomic Grant Challenge award and I look forward to using the NuGEN Single Primer Enrichment Technology (SPET) to screen our sarcoma sample archives."
The Radboud university medical center is considered a center of excellence for sarcoma research with a large archive of sarcoma tissues available as formalin-fixed paraffin-embedded (FFPE) and fresh frozen samples. This grant award pairs the archival resource at Radboud university medical center with NuGEN's Ovation Target Enrichment products, enabling Dr. Tops to efficiently screen large numbers of genes for the detection of novel and previously reported gene fusions.
"We are pleased to be able to support this important study through both financial support and access to our proprietary technology solutions", said Alan Dance, VP of Marketing and Business Development at NuGEN. "It is gratifying to be working with Dr. Tops and the Radboud university medical center where the application of advanced technologies promises to deliver tangible clinical benefits, the potential of new diagnostics, and identification of novel targets for improved therapeutics in the field of oncology."
NuGEN's proprietary Single Primer Enrichment Technology (SPET) is the core technology that delivers a highly sensitive and customizable method for detection of any fusion event in the targeted gene set with as little as 10 ng of total RNA derived from either fresh or formalin-fixed paraffin-embedded tissues. The easy, cost-effective assay employs a single day, rapid workflow.
NuGEN Technologies is the leader in providing solutions which make biological samples accessible for genomic analysis, enabling scientists to capture the truest biology achievable, independent of the quantity or quality of the samples. The company has commercialized numerous proprietary DNA and RNA sample preparation products for use in research and diagnostic applications. Founded in 2000, NuGEN Technologies, Inc. is privately held and headquartered in San Carlos, CA. For more information please visit www.nugen.com
<< back to overview news items